AC Immune SA Stock price
Is AC Immune SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.
Key metrics
AC Immune SA Stock Analysis
Analyst Opinions
10 Analysts have issued a AC Immune SA forecast:
Analyst Opinions
10 Analysts have issued a AC Immune SA forecast:
AC Immune SA Events
Upcoming Event
Don't miss a Thing! We will send you all news about AC Immune SA directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AC Immune SA Stock News
Company Profile
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
| Head office | Switzerland |
| CEO | Prof. Pfeifer |
| Employees | 106 |
| Founded | 2003 |
| Website | www.acimmune.com |


